<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02227641</url>
  </required_header>
  <id_info>
    <org_study_id>AIT-MULTIVIR-01</org_study_id>
    <secondary_id>2012-004240-30</secondary_id>
    <nct_id>NCT02227641</nct_id>
  </id_info>
  <brief_title>Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation</brief_title>
  <official_title>Prospective, Open, Randomized, Two-arm, Controlled, Multicenter Clinical Phase I/IIa Trial to Evaluate the Safety and Efficacy of Adoptive Immunotherapy With Allogeneic CMV/EBV Specific, Peptide Stimulated T-cells (CD3+) for Prevention or Preemptive Therapy of Reactivation of CMV and/or EBV in Patients After Allogeneic, HLA Identical Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Augsburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BayImmuNet Bavarian Immunotherapy Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients after allogeneic stem cell transplantation reactivation of latent herpesviruses
      such as Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) is a frequent and life threatening
      complication requiring antiviral treatment. The underlying problem is a severe suppression of
      the donors immune system after transplantation into the patient. Herpesviruses such as CMV
      and EBV persist after primary infection life long in the host and therefore require constant
      immunological control. This control is largely provided by the T-cell compartment of the
      immune system. After allogeneic stem cell transplantation the T-cell compartment requires a
      long time for its reconstitution since only a small fraction of the donor T-cells are
      transplanted. During this time Herpesviruses can reoccur due to the lack of effective T-cell
      control.

      This study therefore aims at reconstituting the T-cell compartment with CMV and EBV specific
      T-cells at an early time point after allogeneic stem cell transplantation. It is mainly a
      phase I study to demonstrate that these in vitro generated T-cells can be applied safely in
      this patient population. The study also aims at demonstrating the efficacy of CMV/EBV
      specific T-cells by monitoring viral reactivation and use of antiviral drugs. The hypothesis
      is, that CMV/EBV specific T-cell can be applied safely and do not result in graft versus host
      disease and that they successfully prevent reactivation of CMV and EBV after adoptive
      transfer in patients after allogeneic stem cell transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity of adoptive transfer of CMV/EBV specific T-cells</measure>
    <time_frame>1-28 days after adoptive T-cell transfer</time_frame>
    <description>Assessment of acute transfusion toxicity within 24 hours after adoptive T-cell transfer.
Assessment of the development of acute transfusion associated acute graft versus host disease (GvHD) within 28 days after adoptive T-cell transfer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence of preventative/preemptive adoptive transfer of CMV/EBV specific T-cells on virus reactivation</measure>
    <time_frame>During observation period until day 204 post transplantation</time_frame>
    <description>Incidence of reactivation of CMV and/or EBV during the observation period assessed by virus specific PCR of peripheral blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of preventative/preemptive adoptive transfer of CMV/EBV specific T-cells on the use of antiviral therapy</measure>
    <time_frame>During observation period until day 204 post transplantation</time_frame>
    <description>Cumulative dose of Ganciclovir, Valganciclovir, Foscarnet, Cidofovir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of preventative/preemptive adoptive transfer of CMV/EBV specific T-cells on the use of Rituximab</measure>
    <time_frame>During observation period until day 204 post transplantation</time_frame>
    <description>Cumulative dose of Rituximab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of preventative/preemptive adoptive transfer of CMV/EBV specific T-cells on T-cell reconstitution</measure>
    <time_frame>During observation period until day 204 post transplantation</time_frame>
    <description>Immunomonitoring of peripheral blood by flow cytometry.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Patients Undergoing Allogeneic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Adoptive transfer of CMV/EBV specific T-cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repetitive adoptive T-cell transfer starting at day 30 after allogeneic stem cell transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CMV/EBV specific T-cell</intervention_name>
    <description>Peptide stimulated allogeneic T-cells with dual specificity for CMV and EBV</description>
    <arm_group_label>Adoptive transfer of CMV/EBV specific T-cells</arm_group_label>
    <other_name>T cell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for allogeneic stem cell transplantation

          -  HLA identical donor, related or unrelated, 10/10 match

          -  Stem cell source: G-SCF mobilized peripheral blood stem cells

          -  Presence of at least one HLA allele: A0101, A0201, B0702, B0801, B3501, C0702

          -  Positive EBV serology of the donor

          -  Positive CMV serology of the donor

          -  Adequate contraception

        Exclusion Criteria:

          -  Donor CMV seronegative

          -  Donor EBV seronegative

          -  Stem cell source: bone marrow or cord blood

          -  Alemtuzumab for conditioning

          -  Sorror Score &gt;3

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armin H Gerbitz, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernd Spriewald, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Erlangen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anita Kremer, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Erlangen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katja San Niccolo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Erlangen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armin H Gerbitz, MD, PhD</last_name>
    <phone>++49 30 450 565256</phone>
    <email>armin.gerbitz@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anita Kremer, MD, PhD</last_name>
    <phone>++49 9131 8543183</phone>
    <email>anita.kremer@uk-erlangen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Center Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Schmid, MD, PhD</last_name>
      <phone>0049 821 4002736</phone>
    </contact>
    <investigator>
      <last_name>Christoph Schmid, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité University Hospital Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin H Gerbitz, MD, PhD</last_name>
      <phone>++49 30 450565256</phone>
      <email>armin.gerbitz@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Lutz Uharek, MD, PhD</last_name>
      <email>lutz.uharek@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Lutz Uharek, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Armin Gerbitz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitiy Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Kremer, MD, PhD</last_name>
      <phone>++49 9131 8543183</phone>
      <email>anita.kremer@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Bernd Spriewald, MD, PhD</last_name>
      <phone>++49 9131 8543116</phone>
      <email>bernd.spriewald@uk-erlangen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Katja San Niccolo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Wagner, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eva Wagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Munich LMU</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Tischer, MD</last_name>
      <phone>0049 89 70954240</phone>
    </contact>
    <investigator>
      <last_name>Johanna Tischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ernst Holler, MD, PhD</last_name>
      <phone>0049 941 9445570</phone>
    </contact>
    <investigator>
      <last_name>Ernst Holler, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.medizin5.uk-erlangen.de/</url>
    <description>Dept. of Medicine 5, Hematology/Oncology, University of Erlangen</description>
  </link>
  <link>
    <url>http://www.medizin5.uk-erlangen.de/forschung-und-lehre/forschungsschwerpunkte/ag-gerbitz/</url>
    <description>Principal Investigator´s Site</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2014</study_first_submitted>
  <study_first_submitted_qc>August 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2014</study_first_posted>
  <last_update_submitted>June 23, 2016</last_update_submitted>
  <last_update_submitted_qc>June 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CMV</keyword>
  <keyword>Cytomegalovirus</keyword>
  <keyword>EBV</keyword>
  <keyword>Epstein Barr Virus</keyword>
  <keyword>virus</keyword>
  <keyword>T cell</keyword>
  <keyword>adoptive transfer</keyword>
  <keyword>transplantation</keyword>
  <keyword>allogeneic</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

